8 results about "Methamphetamine" patented technology

The invention relates to a polymeric nanomaterial that has specific affinity for MeA (methamphetamine) or AMP (amphetamine-derived synthetic drugs) and can exist at the nanoscale, as well as to the synthesis method thereof.

This invention provides a method for constructing a donor-acceptor type perylene diimide-based porous conjugated polymer probe and detecting methamphetamine and amphetamine solutions. The method synthesizes donor-acceptor type perylene diimide-based porous conjugated polymer probes with different topologies by combining an electron acceptor perylene diimide derivative and an electron donor aggregation-induced emission fluorophore via a succinate coupling reaction. When used for the detection of methamphetamine and amphetamine, this system exhibits a clear ratiometric fluorescence response, with the fluorescence color gradually changing from yellow-green to orange and orange-red, demonstrating a significant ratiometric fluorescence response. It features fast response speed, high detection sensitivity, good selectivity, and no interference from other common structurally and property-similar substances, enabling the differentiation and identification of methamphetamine and amphetamine.

This invention discloses a method for rapid quantitative analysis of methamphetamine based on portable near-infrared spectroscopy and PLS modeling, characterized by: (1) collecting near-infrared diffuse reflectance spectra of methamphetamine crystals and tablets using a portable near-infrared analyzer, and preprocessing the spectral data using the S-G method; (2) performing data analysis and modeling based on the PLS method to obtain a PLS regression model; (3) detecting the sample to be tested: collecting the near-infrared diffuse reflectance spectra of the sample to be tested, and then obtaining the methamphetamine content in the sample to be tested according to the model in step (2).

The application relates to a marker, a kit and an application for differentiating methamphetamine-induced psychosis from primary schizophrenia, and belongs to the technical field of biological medicine and judicial expertise. The application provides application of miRNA as a marker in preparation of a product for differentiating methamphetamine-induced psychosis from primary schizophrenia, wherein the miRNA comprises at least one of hsa-miR-11400, hsa-miR-1908-3p, hsa-miR-4433b-3p and nov-miR-chr20. The application takes nov-miR-chr20 as a forward specific marker of PS, and takes the other three miRNAs as forward indicating markers of MAP, effectively avoids false positive or false negative, improves the specificity and sensitivity of detection, ensures stability and repeatability, and solves the misdiagnosis problem caused by high overlap and similarity of MAP and PS.

Styrene compounds, methods for preparing the same, and uses thereof in the preparation of medicaments for treating drug addiction and alleviating withdrawal symptoms. Disclosed are styrene compounds having the structure of Formula III: or stereoisomers, deuterated compounds, or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 are each independently selected from hydrogen, hydroxyl, alkoxy, or phosphate; L is selected from carbonyl or methylene; X is selected from O; R 4 is selected from hydrogen, C1-C 10 linear or branched alkyl, C3-C 10 cycloalkyl, aralkyl, hydroxyalkyl, or carbonylalkyl. The styrene compounds of the present invention not only intervene in METH-induced reward behavior, but also improve negative emotional behaviors such as depression and anxiety commonly seen during withdrawal, and have a dual value of significantly alleviating both addiction symptom formation and withdrawal symptoms. Disclosed are uses of the styrene compounds or stereoisomers, deuterated compounds, or pharmaceutically acceptable salts thereof in the preparation of medicaments for preventing and / or treating methamphetamine addiction and alleviating depression and anxiety-like behaviors caused by methamphetamine withdrawal.

This invention provides a donor-acceptor type perylene diimide-based porous conjugated polymer sensing membrane for distinguishing between methamphetamine and amphetamine atmospheres. The membrane is prepared by spin-coating a homogeneous mixture of the donor-acceptor type perylene diimide porous conjugated polymer, polystyrene, and a solvent. When used for the detection of methamphetamine and amphetamine atmospheres, the system exhibits a significant differential ratio fluorescence response, achieving quantitative and differential detection of methamphetamine and amphetamine atmospheres in the ranges of 0-600 ppm and 0-1500 ppm, respectively. It offers advantages such as fast response, simple detection process, high sensitivity, and good selectivity, without interference from other common structurally and property-similar substances. This provides a research solution for the on-site identification and differentiation of hazardous chemicals with similar structures and properties.

This application relates to the field of biomedical technology, and in particular to the application of N-acetylneuraminic acid in the preparation of drugs for treating methamphetamine addiction. This application is the first to discover the key role of N-acetylneuraminic acid (Neu5Ac) in the treatment of methamphetamine addiction, which can significantly reduce the CPP score in methamphetamine-addicted mice, demonstrating a good therapeutic effect on methamphetamine addiction. Furthermore, Neu5Ac can be synthesized endogenously, exhibiting advantages such as good biocompatibility and low toxicity.